



AI-Driven Preventive Healthcare: Business Challenges and Opportunities in Cardiovascular Diagnostics

Youssef Issa

Haaga-Helia University of Applied Sciences
Bachelors of Business Information Technology
Bachelor's Thesis
2025

Abstract

Author(s) Youssef Issa
Degree Bachelor of Business Information Technology
Report/Thesis Title AI-Driven Preventive Healthcare: Business Challenges and Opportunities in Cardiovascular Diagnostics
Number of pages and appendix pages 42
<p>This study explores the business challenges and opportunities associated with the adoption of AI-driven preventive healthcare solutions in cardiovascular diagnostics. The research focuses on understanding the key barriers to AI implementation and the potential benefits it offers for improving healthcare outcomes.</p> <p>The literature review examines previous research on AI applications in healthcare, particularly cardiovascular diagnostics, highlighting both the technological advancements and the challenges faced in the adoption of AI. It also explores existing business models, regulatory considerations, and ethical concerns surrounding AI in healthcare.</p> <p>A qualitative research design was employed, utilizing semi-structured interviews with healthcare professionals and industry experts to gather insights into the business challenges and opportunities of AI in preventive cardiovascular healthcare. Thematic analysis was conducted to identify key themes and sub-themes from the interview data.</p> <p>The study identified several significant challenges to the adoption of AI, including clinical skepticism, data privacy concerns, and integration issues with existing healthcare systems. On the other hand, promising business opportunities were found in AI-powered diagnostic imaging, risk prediction platforms, and remote monitoring technologies, which have the potential to improve patient outcomes and reduce healthcare costs.</p> <p>The study concludes that while AI offers significant opportunities to enhance cardiovascular diagnostics, overcoming barriers such as clinical trust, regulatory hurdles, and integration challenges is essential for its widespread adoption. The research provides insights for both practitioners and AI developers to consider when implementing AI solutions in healthcare settings. The research acknowledges limitations such as a small sample size and the geographical scope of the study. Future work should include broader geographic studies, longitudinal research, and wider stakeholder involvement to fully understand the impact of AI in healthcare.</p>
Key words AI-driven healthcare, cardiovascular diagnostics, business challenges, diagnostic imaging, risk prediction, healthcare integration

Table of Contents

1 Introduction	1
1.1 Research Background	1
1.2 Research Problem.....	3
1.3 Research Objectives	3
1.4 Research Questions	3
1.5 Significance of the Research	3
1.6 Research Limitations	4
1.7 Thesis Structure	5
1.8 Expected Contribution	5
2 Literature Review	6
2.1 Definition of AI and its Applications in Healthcare	6
2.2 Role of AI in Preventive Medicine	6
2.3 Focus on Cardiovascular Health.....	7
2.4 Overview of Cardiovascular Diseases (CVDs)	8
2.5 Importance of Early Detection and Prevention	9
2.6 Current Methods and Tools for Cardiovascular Diagnostics	10
2.7 Machine Learning and Deep Learning in Diagnostics	10
2.8 AI in Medical Imaging	11
2.9 Business Models for AI in Preventive Medicine	12
2.10 Challenges in AI-Powered Preventive Healthcare.....	13
2.10.1 Technical Challenges	13
2.10.2 Ethical Challenges.....	14
2.10.3 Regulatory Challenges	14
2.11 The Role of Ultrasound in Reducing Health Inequalities	16
2.11.1 Case Study: Aiatella	17
2.12 Summary of Literature Review.....	17
3 Empirical Part	19
3.1 Research Conduction	19
3.2 Research Methods Adopted	19
3.3 Data Collection Process	20
3.4 Data Analysis Method.....	21
4 Results and Findings	22
4.1 Demographic Information	22
4.2 Thematic Analysis	22
4.2.1 Generate Initial Codes Based on the Interview Data.....	22

4.3 Search for Themes	26
5 Discussion	29
5.1 Key Business Challenges	29
5.1.1 Clinical Skepticism and Trust in AI Solutions	29
5.1.2 Product-Solution Fit and Market Penetration	29
5.1.3 Data Privacy and Integration Issues	30
5.2 Business Opportunities in AI-Driven Preventive Healthcare.....	30
5.2.1 AI-Powered Diagnostic Imaging.....	30
5.2.2 AI for Risk Prediction and Early Intervention.....	30
5.2.3 Wearables and Remote Monitoring	31
5.2.4 Scalability and Integration into Value-Based Care	31
6 Conclusion and Future Work.....	32
6.1 Research Limitations	33
6.2 Future Work.....	33
Sources	34
Appendices	42
Appendix 1. Interview Questions	42

1 Introduction

1.1 Research Background

Cardiovascular diseases (CVDs) remain one of the most significant public health concerns globally, accounting for approximately 17.9 million deaths annually (Luo et al. 2024). The growing prevalence of CVDs necessitates a shift in focus from reactive treatment to proactive prevention. Preventive healthcare emphasizes early risk assessment, lifestyle modifications, and medical interventions aimed at reducing disease progression and preventing life-threatening events such as heart attacks and strokes.

The effectiveness of preventive healthcare is well-established, with numerous studies indicating that early identification and intervention can significantly reduce morbidity and mortality associated with CVDs (Gruson et al. 2025). Key strategies include routine screenings, risk factor management, and lifestyle counseling, which, when integrated with advanced medical technologies, further enhance preventive efforts. Emerging approaches, such as exposome analysis, allow for a comprehensive assessment of environmental and genetic factors influencing cardiovascular health, enabling personalized prevention strategies (Gruson et al. 2025).

Despite the known benefits of prevention, challenges such as limited access to healthcare, socioeconomic disparities, and lack of awareness continue to hinder widespread adoption. Moreover, traditional diagnostic tools like electrocardiograms (ECGs), blood pressure monitoring, and lipid profiling, though essential, have limitations in predicting future cardiovascular events with high accuracy (Tallukder et al. 2025). This has led to increasing interest in artificial intelligence (AI)-driven solutions that offer more precise and early detection capabilities.

Artificial Intelligence (AI) is revolutionizing healthcare diagnostics, particularly in cardiovascular medicine. AI algorithms have demonstrated remarkable potential in predicting, detecting, and managing CVDs with higher accuracy and efficiency than conventional methods. AI-driven models analyze large datasets, identifying complex patterns that might not be immediately evident to human clinicians, thus aiding in early diagnosis and personalized treatment planning (Rajeev & Natarajan 2025).

One of the most promising applications of AI in preventive cardiovascular healthcare is predictive modeling. AI-powered systems can assess various risk factors, including genetic predisposition, lifestyle behaviors, and medical history, to forecast an individual's likelihood of developing CVDs. Hybrid explainable AI-based machine learning (HXAI-ML) models have been developed to improve the accuracy of heart disease detection by integrating clinical and diagnostic data into predictive analytics

(Talukder et al. 2025). These models surpass traditional risk assessment tools, providing more reliable predictions that facilitate timely interventions.

In addition to predictive analytics, AI is also making significant strides in medical imaging. AI-enhanced imaging technologies, such as deep learning algorithms for echocardiography and cardiac magnetic resonance imaging (CMR), have been shown to detect cardiovascular abnormalities with greater precision than traditional interpretation methods (Jafari et al. 2023). AI-driven image segmentation and pattern recognition enable automated identification of conditions such as myocardial infarction, arrhythmias, and valvular disorders, thereby improving diagnostic accuracy and reducing the workload of healthcare professionals.

Moreover, AI has the potential to revolutionize cardiovascular risk assessment through non-invasive techniques. For instance, retinal fundus image analysis, powered by AI, has been increasingly utilized to detect cardiovascular risk markers by analyzing microvascular changes in the eye (Abdollahi et al. 2024). This approach provides a cost-effective and accessible means of screening individuals for early signs of cardiovascular conditions without requiring extensive medical equipment.

While AI presents numerous advantages in healthcare diagnostics, its integration into clinical practice is not without challenges. One of the primary concerns is data privacy and security. AI systems rely on vast amounts of patient data for training and optimization, raising concerns about confidentiality and potential misuse of sensitive health information. Compliance with regulatory frameworks, such as the General Data Protection Regulation (GDPR) and Health Insurance Portability and Accountability Act (HIPAA), is crucial to ensure ethical AI deployment in healthcare settings (Ahmed et al. 2023).

Another challenge is the interpretability of AI models. Many deep learning algorithms operate as "black boxes," making it difficult for clinicians to understand how decisions are made. This lack of transparency can hinder trust and acceptance among healthcare providers and patients. To address this issue, researchers are focusing on explainable AI (XAI) frameworks that provide clear, interpretable insights into AI-driven decision-making processes (Rajeev & Natarajan 2025).

Moreover, the successful implementation of AI in cardiovascular diagnostics requires robust validation and integration into existing healthcare infrastructures. Clinical adoption of AI-powered tools necessitates extensive real-world testing, regulatory approvals, and seamless interoperability with electronic health records (EHRs). Resistance to technological change among healthcare professionals further poses a barrier to AI adoption. Therefore, targeted training programs and interdisciplinary collaboration between AI developers and clinicians are essential to facilitate smooth integration.

The future of AI-driven preventive healthcare is promising, with ongoing research and technological advancements paving the way for more precise, accessible, and cost-effective solutions. AI-driven wearable devices and remote monitoring systems are emerging as valuable tools for continuous cardiovascular health assessment. Smartwatches and biosensors equipped with AI algorithms can track heart rate variability, detect arrhythmias, and monitor blood pressure in real-time, providing early warnings of potential cardiac events (Luo et al. 2024).

1.2 Research Problem

Current cardiovascular diagnostics face several challenges, including late disease detection, reliance on traditional diagnostic methods with limited predictive capabilities, and the need for specialized clinical expertise. Many existing diagnostic tools, such as electrocardiograms (ECGs) and cardiac imaging, often fail to detect early-stage cardiovascular diseases (CVDs), leading to delayed interventions and increased mortality rates. Additionally, the growing burden of cardiovascular diseases worldwide necessitates more efficient, accurate, and accessible diagnostic solutions. AI-driven solutions in preventive healthcare offer a promising approach to address these limitations by enabling early disease prediction, automating diagnostics, and personalizing patient risk assessments. However, despite advancements in AI applications, challenges such as data privacy, integration into clinical workflows, and the need for robust validation hinder widespread adoption. Addressing these barriers is crucial to fully leveraging AI-driven preventive healthcare in cardiovascular diagnostics and improving patient outcomes.

1.3 Research Objectives

- To explore the key business challenges in implementing AI-driven preventive healthcare in cardiovascular diagnostics.
- To explore the business opportunities AI offers for cardiovascular diagnostics.

1.4 Research Questions

1. What are the key business challenges in implementing AI-driven preventive healthcare in cardiovascular diagnostics?
2. What business opportunities does AI offer for cardiovascular diagnostics?

1.5 Significance of the Research

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, accounting for approximately 17.9 million deaths annually (Luo et al. 2024). Early detection and prevention are

crucial in reducing this burden; however, current diagnostic methods often fall short in identifying asymptomatic individuals at risk. Traditional tools like electrocardiograms (ECGs) and imaging techniques require specialized interpretation and may not detect subtle, early-stage abnormalities (Muhammad Ali Muzammil et al. 2024). This limitation underscores the need for more advanced, accessible, and accurate diagnostic approaches.

Artificial intelligence (AI) has demonstrated significant potential in transforming cardiovascular diagnostics. For instance, AI algorithms have been developed to analyze retinal fundus images, enabling the assessment of cardiovascular risk factors through non-invasive means (Arnould et al. 2022). This approach not only facilitates early detection but also offers a cost-effective alternative to traditional methods. Moreover, AI-driven predictive models have been shown to outperform conventional risk assessment tools. A study comparing an AI-based platform, ORAiCLE, with the traditional Framingham risk score found that the AI model was up to 12% more accurate in predicting five-year cardiovascular events, particularly in high-risk individuals. (Vaghefi et al. 2022)

Despite these advancements, challenges persist in implementing AI-driven solutions in clinical practice. Issues such as data privacy, integration into existing healthcare systems, and the need for extensive validation studies hinder widespread adoption (Ahmed et al. 2023). Addressing these challenges is essential to fully realize the benefits of AI in preventive cardiovascular healthcare.

AIATELLA, a pioneering company in AI-driven healthcare solutions, aims to revolutionize preventive cardiovascular diagnostics through advanced machine learning algorithms and predictive analytics. This research will provide AIATELLA with critical insights into the business challenges and opportunities associated with implementing AI in preventive healthcare, guiding strategic decision-making for product development and market expansion. By addressing cost-effectiveness, scalability, and adoption barriers, the findings will help AIATELLA refine its AI-driven diagnostic tools, enhance early disease detection, and optimize resource allocation. The results of this research can be utilized in AIATELLA's product innovation, policy recommendations, and expansion strategies, ultimately improving healthcare accessibility, reducing treatment costs, and enhancing patient outcomes.

1.6 Research Limitations

This research will focus specifically on the business challenges and opportunities of implementing AI-driven preventive healthcare in cardiovascular diagnostics, excluding broader AI applications in general healthcare and treatment-based AI interventions. The study will include aspects such as cost implications, scalability, socio-economic barriers, and AI's potential in early disease detection but will not cover technical algorithm development or deep AI model training, as these fall outside

the business and policy scope. This limitation ensures a targeted approach, making the research actionable for AIATELLA and relevant stakeholders in healthcare innovation.

1.7 Thesis Structure

The thesis follows a structured approach to exploring AI-driven healthcare and its impact on cardiovascular diagnostics. The theoretical background establishes the foundation, followed by research methodology detailing the study design. The business case analysis evaluates AI adoption in healthcare, while potential solutions and recommendations propose strategies for overcoming challenges. The conclusion summarizes key findings and future implications.

1.8 Expected Contribution

This research aims to contribute significantly to AI-driven healthcare, specifically in the domain of cardiovascular diagnostics. By integrating advanced machine learning models and predictive analytics, the study will offer new insights into how AI can enhance early disease detection, optimize treatment pathways, and improve patient outcomes. The findings will contribute to the growing body of knowledge on AI applications in healthcare, addressing key technical and operational challenges.

Beyond clinical impact, this research will provide valuable perspectives on the business implications of AI adoption in preventive healthcare. It will explore cost-effectiveness, potential scalability, and regulatory considerations for AI-driven diagnostics. Additionally, the study will analyze how AI can be integrated into existing healthcare infrastructure while ensuring ethical compliance and data security. The results will help shape strategic business decisions for healthcare organizations, policymakers, and technology developers, leading to more efficient and accessible cardiovascular healthcare solutions. Ultimately, this thesis aspires to bridge the gap between AI technology and real-world healthcare needs, fostering innovation in preventive medicine and public health.

2 Literature Review

2.1 Definition of AI and its Applications in Healthcare

Artificial Intelligence (AI) refers to the simulation of human intelligence in machines, enabling them to perform tasks such as learning, reasoning, and decision-making. In healthcare, AI has been widely adopted for its ability to analyze vast datasets, identify patterns, and assist in clinical decision-making. The primary applications of AI in healthcare include disease diagnostics, personalized treatment planning, robotic surgeries, drug discovery, and remote patient monitoring (Nori et al. 2025). Machine learning (ML), a subset of AI, enhances clinical decision support systems (CDSS) by analyzing electronic health records (EHRs) to predict disease risks and recommend preventive interventions.

AI is revolutionizing diagnostics by improving the accuracy and efficiency of medical imaging and laboratory test interpretations. Deep learning algorithms are being used to detect abnormalities in radiological scans, such as X-rays, MRIs, and CT scans, with performance comparable to or exceeding that of human radiologists (Bhandari 2024). Additionally, AI-powered diagnostic tools are capable of identifying early signs of diseases, such as diabetic retinopathy and cardiovascular conditions, by analyzing retinal fundus images and ECG recordings (Alsadoun et al. 2024). These advancements enable early disease detection, allowing for timely intervention and improved patient outcomes.

In treatment, AI facilitates precision medicine by analyzing genetic, clinical, and lifestyle data to develop tailored therapies for individual patients. AI-driven drug discovery accelerates the identification of novel drug candidates by predicting molecular interactions and potential side effects (Blanco-González et al. 2023). AI-assisted robotic surgeries, such as the da Vinci Surgical System, enhance surgical precision, reduce recovery time, and minimize complications (Knudsen et al. 2024).

AI also plays a critical role in preventive care by enabling real-time health monitoring through wearable devices. Smartwatches and biosensors equipped with AI algorithms continuously track vital signs, detect irregularities, and alert healthcare providers about potential health risks. Predictive analytics further assists in population health management by identifying at-risk individuals and optimizing resource allocation for preventive interventions (Nori et al. 2025).

2.2 Role of AI in Preventive Medicine

Preventive medicine plays a crucial role in reducing healthcare costs and improving patient outcomes by focusing on early detection, risk assessment, and intervention before the onset of diseases (Fahim & Fahim 2024). Chronic conditions such as cardiovascular diseases, diabetes, and cancer contribute significantly to global healthcare expenditures, often requiring expensive treatments when

detected at advanced stages. The integration of AI into preventive medicine enables the development of predictive models that analyze vast datasets, including electronic health records (EHRs), genetic profiles, and lifestyle factors, to identify individuals at high risk of developing diseases (Dixon et al. 2024). AI-driven screening methods enhance the efficiency of preventive strategies by automating risk assessments, enabling early interventions, and reducing the burden on healthcare systems. (Bikash Behera et al. 2025)

AI-driven predictive analytics in preventive healthcare utilizes machine learning algorithms to analyze patient data and detect patterns indicative of future health risks. For example, AI models have been successfully employed in cardiovascular risk prediction by evaluating clinical parameters such as blood pressure, cholesterol levels, and ECG abnormalities. These AI-powered tools allow healthcare providers to stratify patients based on their risk levels and recommend personalized lifestyle modifications or early pharmacological interventions (Conners et al. 2024). Additionally, AI applications in wearable technology, such as smartwatches and biosensors, continuously monitor vital signs and detect anomalies in real time, enabling early warnings for conditions like arrhythmias or hypertension.

Beyond individual patient care, AI contributes to population health management by identifying public health trends and optimizing resource allocation. AI-driven epidemiological models can forecast disease outbreaks and guide public health policies to implement timely interventions. Moreover, AI-powered chatbots and digital health assistants provide personalized recommendations for preventive measures, improving health literacy and encouraging proactive healthcare behaviors. By facilitating data-driven decision-making, AI enhances the efficiency of preventive medicine and contributes to reducing long-term healthcare costs while improving overall public health outcomes (Bikash Behera et al. 2025).

2.3 Focus on Cardiovascular Health

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, contributing to an estimated 32% of all global deaths (The Agha Khan University Hospital 2019). A significant portion of these deaths result from preventable risk factors such as hypertension, obesity, diabetes, and sedentary lifestyles. The financial burden of CVDs on healthcare systems is immense, with billions of dollars spent annually on treatment, hospitalization, and long-term management of cardiovascular conditions. Early diagnosis and prevention are critical to mitigating these costs and improving patient outcomes. AI-driven solutions are increasingly being integrated into cardiovascular diagnostics and risk assessment to enhance early detection, optimize treatment pathways, and personalize prevention strategies (Olawade et al. 2024).

A study by Shabeer et al. (2025) highlights the application of AI in cardiovascular diagnostics, emphasizing its ability to analyze vast amounts of clinical data, detect hidden patterns, and provide accurate risk predictions. AI models trained on electrocardiograms (ECGs) and echocardiograms can identify subtle abnormalities that may go unnoticed in conventional diagnostic settings, enabling earlier intervention. Additionally, machine learning algorithms have demonstrated superior accuracy in predicting heart failure risk, myocardial infarction, and arrhythmias compared to traditional risk assessment models. These AI-driven approaches significantly reduce diagnostic errors and facilitate more effective treatment plans.

AI-powered wearable devices, such as smartwatches and biosensors, are revolutionizing cardiovascular health monitoring by continuously tracking vital signs and detecting anomalies in real-time (Vo & Trinh 2024). These devices use AI algorithms to identify patterns in heart rate variability, blood pressure fluctuations, and respiratory rates, alerting both patients and healthcare providers to potential cardiovascular events. Furthermore, AI-integrated imaging techniques, such as deep learning-enhanced cardiac MRI analysis, have improved the accuracy of diagnosing conditions like coronary artery disease and valvular disorders. The ability of AI to process and interpret complex cardiovascular data efficiently is transforming the field of preventive cardiology, enabling a shift from reactive treatment to proactive disease management (Olawade et al. 2024).

2.4 Overview of Cardiovascular Diseases (CVDs)

Cardiovascular diseases (CVDs) encompass a range of conditions affecting the heart and blood vessels, including coronary artery disease (CAD), heart failure, stroke, and peripheral arterial disease (NHS 2022). CVDs are the leading cause of mortality worldwide, accounting millions of deaths annually. The primary risk factors contributing to CVDs include hypertension, diabetes, obesity, smoking, sedentary lifestyles, and poor dietary habits. Preventive strategies, such as early screening, lifestyle modifications, and medication management, play a crucial role in reducing the burden of these diseases (Kaminsky et al. 2021). Despite advancements in medical treatment, the prevalence of CVDs continues to rise due to aging populations and increasing exposure to modifiable risk factors.

A study by Ramón Luengo-Fernández et al. (2023) highlights the substantial economic burden posed by CVDs on global healthcare systems. Cardiovascular disease (CVD) imposes an estimated annual financial burden of €282 billion on the European Union, with healthcare and long-term care expenses contributing €155 billion (55%), equivalent to 11% of the EU's total health expenditure. Productivity losses due to CVD account for €48 billion (17%), while informal caregiving costs amount to €79 billion (28%). On a per capita basis, the economic impact of CVD is approximately €630, varying

from €381 in Cyprus to €903 in Germany. Among the total CVD costs, coronary heart disease represents 27% (€77 billion), and cerebrovascular diseases account for another 27% (€76 billion).

In addition to direct medical costs, indirect costs such as loss of productivity, disability-adjusted life years (DALYs), and premature mortality significantly impact national economies. Low- and middle-income countries bear a disproportionate burden of CVDs due to limited access to healthcare resources, inadequate preventive programs, and higher exposure to risk factors (Wurie & Cappuccio 2012). The economic strain of CVDs extends beyond healthcare expenses, affecting workforce efficiency and placing financial stress on families dealing with chronic illness and long-term care.

The social burden of CVDs is equally concerning, as these diseases contribute to diminished quality of life, mental health issues, and increased dependency on caregivers. Patients diagnosed with heart disease or stroke often experience long-term physical impairments, which can lead to social isolation and decreased participation in daily activities. The psychological impact of CVDs, including anxiety and depression, further exacerbates the health burden. Public health initiatives aimed at improving awareness, promoting cardiovascular screenings, and encouraging healthier lifestyles are essential in mitigating the widespread effects of CVDs (World Heart Federation n.d.).

2.5 Importance of Early Detection and Prevention

Early detection of cardiovascular diseases (CVDs) is essential for reducing mortality rates and improving long-term patient outcomes (NHS 2019). Timely diagnosis allows healthcare providers to implement targeted interventions, preventing disease progression and reducing the risk of fatal complications such as heart attacks and strokes. Advances in diagnostic tools, including biomarker analysis, electrocardiography (ECG), and imaging techniques, have improved the accuracy and efficiency of early CVD detection (Almansouri et al. 2024). Machine learning algorithms and AI-driven predictive models further enhance risk assessment by analyzing vast datasets, identifying at-risk individuals, and recommending personalized preventive measures (Kalogiannidis et al. 2024).

Preventive strategies such as lifestyle modifications, regular screenings, and early pharmacological interventions can significantly lower the incidence of severe cardiovascular events (Ghodeswar et al. 2023). Population-wide initiatives, including smoking cessation programs, dietary interventions, and physical activity promotion, contribute to reducing modifiable risk factors associated with CVDs (Rippe 2018). These measures not only improve individual health outcomes but also decrease hospital admissions and healthcare expenditures linked to chronic cardiovascular conditions.

The cost-effectiveness of preventive healthcare is evident in its ability to reduce the need for expensive surgical procedures, long-term medication, and intensive care for advanced-stage cardiovascular diseases (Eze-Nliam et al. 2014). AI-driven health monitoring systems, such as wearable devices

and remote patient monitoring platforms, enable continuous tracking of vital signs, allowing for early detection of abnormalities and timely intervention. By shifting the focus from treatment to prevention, healthcare systems can allocate resources more efficiently, improving patient quality of life while minimizing economic strain.

2.6 Current Methods and Tools for Cardiovascular Diagnostics

Traditional cardiovascular diagnostic tools include electrocardiograms (ECGs), echocardiography, cardiac catheterization, and blood tests. ECGs are widely used to measure the electrical activity of the heart, assisting in detecting arrhythmias, myocardial infarctions, and other cardiac abnormalities (Sattar & Chhabra 2023). Echocardiography, which uses ultrasound imaging, provides detailed information on heart structure and function, making it essential for diagnosing heart valve diseases and cardiomyopathies. Blood tests, including lipid profiles and cardiac biomarkers such as troponins, play a critical role in detecting heart attacks and assessing cardiovascular risk. Cardiac catheterization remains a gold standard for diagnosing coronary artery disease, allowing for direct visualization of arterial blockages and assessment of blood flow (Meyers & Vlachos 2025).

A study by Carrington et al. (2022) discusses the limitations of these traditional diagnostic methods, particularly in resource-limited settings. While ECGs are accessible and inexpensive, they often fail to detect intermittent arrhythmias or provide detailed anatomical insights. Echocardiography, although highly effective, is operator-dependent and requires specialized training, making it less available in low-resource healthcare environments. Cardiac catheterization, while highly accurate, is invasive, costly, and associated with potential complications such as bleeding and infections. Furthermore, blood tests, though useful in detecting biomarkers, lack specificity and cannot provide real-time structural or functional assessments of the heart.

In many developing regions, the high cost and limited availability of advanced cardiovascular diagnostic tools contribute to delayed diagnoses and poor patient outcomes. Portable and AI-driven diagnostic solutions are emerging to address these gaps by providing more accessible, cost-effective, and automated cardiovascular assessments. However, challenges such as data standardization, regulatory approval, and integration into existing healthcare systems remain barriers to widespread implementation.

2.7 Machine Learning and Deep Learning in Diagnostics

Machine learning (ML) and deep learning (DL) algorithms are transforming cardiovascular diagnostics by analyzing vast amounts of clinical and imaging data with high accuracy and efficiency (Xia et al. 2024). ML models are widely used in electrocardiogram (ECG) analysis to detect arrhythmias, myocardial infarctions, and other cardiac abnormalities. Supervised learning techniques, such as

logistic regression and support vector machines, have shown promise in predicting heart disease based on patient history and biomarker data. Deep learning models, particularly convolutional neural networks (CNNs), have been successfully applied to echocardiography and cardiac MRI segmentation, improving diagnostic precision by automating the identification of structural abnormalities in the heart (Chen et al. 2020).

A study by Deon and Jackson (2025) highlights the role of ML and DL in processing large datasets, particularly in electronic health records (EHRs) and imaging diagnostics. AI-driven models analyze patterns in ECG signals, angiographic images, and patient history to identify high-risk individuals and suggest early interventions. DL techniques, including recurrent neural networks (RNNs) and transformer-based models, enhance predictive analytics by incorporating time-series data, enabling real-time monitoring of cardiovascular health. These AI-powered systems reduce diagnostic errors and assist clinicians in making data-driven treatment decisions.

Furthermore, ML and DL technologies are improving automated detection in wearable devices, which continuously monitor heart rate variability, blood pressure, and oxygen saturation (Shajari et al. 2023). These real-time analytics allow for early warning systems in patients at risk of sudden cardiac events. Despite these advancements, challenges remain in the standardization of AI models, data privacy concerns, and the need for regulatory approval before clinical implementation. The integration of AI into cardiovascular diagnostics represents a paradigm shift in preventive medicine, reducing the reliance on traditional, time-intensive diagnostic procedures while enhancing accuracy and efficiency.

2.8 AI in Medical Imaging

Artificial intelligence (AI) is revolutionizing cardiovascular imaging by enhancing diagnostic accuracy and efficiency in modalities such as echocardiography, computed tomography (CT), and magnetic resonance imaging (MRI). AI algorithms assist in real-time image acquisition, automate measurements, and improve anomaly detection, reducing operator dependency and inter-observer variability. Machine learning (ML) models integrated with echocardiography have demonstrated superior performance in detecting structural abnormalities, including left ventricular dysfunction and valvular heart disease. Deep learning (DL) techniques, particularly convolutional neural networks (CNNs), are being used to analyze ultrasound images, ensuring precise identification of cardiac pathologies with minimal human intervention (Tian & Liu 2025).

A study by Dos Santos et al. (2025) highlights AI-powered point-of-care ultrasound (POCUS) solutions that significantly improve early heart failure detection in primary care settings. AI-assisted PO-

CUS enhances diagnostic accuracy by providing automated cardiac chamber quantification, improving the identification of reduced ejection fraction and early signs of myocardial dysfunction. In addition, AI-driven cardiac MRI segmentation tools facilitate more accurate assessments of myocardial fibrosis and ischemia, outperforming traditional manual analysis.

AI-integrated imaging technologies also address key limitations in resource-limited settings by offering portable, cost-effective diagnostic solutions. Automated image interpretation minimizes the need for highly trained specialists, allowing broader access to cardiovascular diagnostics in remote areas. Moreover, AI-powered Doppler echocardiography improves the detection of hemodynamic abnormalities, aiding in the early identification of atherosclerosis and hypertension-related complications. The combination of AI and imaging modalities significantly enhances clinical decision-making, ensuring timely and accurate diagnosis of cardiovascular diseases (Tian & Liu 2025).

2.9 Business Models for AI in Preventive Medicine

Healthcare business models are evolving to accommodate advancements in artificial intelligence (AI), particularly in preventive medicine. Traditional models include subscription-based, pay-per-use, and value-based care. Subscription-based models, commonly used in telemedicine and health monitoring services, offer continuous access to healthcare services through a fixed monthly or annual fee. Pay-per-use models, often seen in diagnostic services and AI-driven health assessments, allow patients to pay only for the specific service they receive. Value-based care models focus on patient outcomes, incentivizing healthcare providers to implement preventive strategies that reduce hospital readmissions and improve overall health metrics. These models increasingly integrate AI-powered technologies to enhance service delivery and optimize healthcare costs. (Mbanugo & Unanah 2025)

A study by Baklola and Terra (2024) highlights how AI-driven business models are transforming preventive healthcare by leveraging predictive analytics, real-time monitoring, and personalized interventions. AI-powered health monitoring apps use machine learning algorithms to track vital signs, detect anomalies, and provide personalized health recommendations. These applications are integrated into wearable devices such as smartwatches and biosensors, enabling continuous cardiovascular monitoring and early detection of potential health risks. AI-assisted diagnostic tools, such as automated ECG analysis and AI-enhanced imaging systems, improve early disease detection and reduce diagnostic errors. Additionally, AI-driven telehealth platforms use natural language processing and chatbot interfaces to provide real-time medical consultations, increasing accessibility to preventive care in remote areas.

Despite these advancements, implementing AI-driven business models in healthcare presents several challenges. High implementation costs, including the development, integration, and maintenance of AI systems, pose financial barriers for smaller healthcare providers. Scalability issues arise due to differences in healthcare infrastructure, regulatory requirements, and interoperability between AI systems and existing electronic health records. Resistance to AI adoption among healthcare professionals and patients is another hurdle, driven by concerns over data privacy, algorithm transparency, and trust in AI-generated recommendations (Kumar Das et al. 2024). Cultural and socio-economic factors also influence the adoption of AI in resource-limited settings, where limited internet access, inadequate funding, and a lack of digital literacy hinder the widespread deployment of AI-driven preventive healthcare solutions (Scoble 2025).

2.10 Challenges in AI-Powered Preventive Healthcare

2.10.1 Technical Challenges

Data collection and model training are major challenges in AI-powered preventive healthcare, as they require high-quality, diverse, and representative datasets to ensure accurate predictions. AI models rely on large-scale clinical and imaging datasets, but inconsistencies in data collection methods, biases in sample populations, and missing or incomplete health records affect model performance. Moreover, real-world patient data often come from different healthcare providers and electronic health record (EHR) systems, leading to challenges in data integration and standardization. Ensuring interoperability between different data sources remains a persistent issue in AI-driven preventive healthcare (Mbanugo 2025).

A study by Chumachenko and Yakovlev (2025) highlights the difficulties in training AI models for disease prediction due to variations in healthcare infrastructure and diagnostic protocols across different regions. AI models trained on data from high-resource settings may not generalize well to populations in low-resource areas. Additionally, model accuracy is impacted by the presence of noise in medical images, incomplete patient histories, and variations in clinician input. These factors contribute to AI's susceptibility to false positives and false negatives, reducing its reliability in real-world clinical applications.

Integrating AI tools into existing healthcare systems presents further challenges, particularly due to compatibility issues with legacy EHR systems. Many hospitals and clinics operate on outdated digital infrastructure, which limits the seamless deployment of AI algorithms. The lack of standardized regulatory guidelines also creates uncertainty regarding AI adoption in preventive healthcare. Healthcare providers are often hesitant to trust AI-driven diagnostics, citing concerns over liability, accountability, and ethical implications of machine-generated medical decisions (Gerke et al. 2020).

2.10.2 Ethical Challenges

Bias in AI algorithms remains a significant ethical challenge in preventive healthcare. AI models trained on biased datasets may disproportionately favor certain demographic groups, leading to disparities in disease prediction and diagnosis. This issue is particularly concerning in cardiovascular diagnostics, where underrepresentation of minority populations in training data can result in misdiagnosis or delayed detection of conditions such as hypertension and heart disease. Addressing algorithmic bias requires diverse and representative datasets, as well as continuous auditing and refinement of AI models to ensure fairness and equity in healthcare outcomes. (Ueda et al. 2023)

A study by Marey et al. (2024) highlights concerns regarding transparency in AI-powered healthcare decision-making. Many AI models operate as "black boxes," meaning their decision-making processes are not fully explainable to clinicians or patients. This lack of transparency raises issues of accountability, as healthcare professionals may struggle to justify AI-generated recommendations. Ethical AI frameworks emphasize the importance of explainability, where AI systems should provide interpretable and actionable insights rather than relying on complex, opaque algorithms.

According to Tilala et al. (2024) Patient privacy is another critical ethical concern, as AI-driven preventive healthcare relies on vast amounts of personal health data. Ensuring data security and compliance with regulations such as the General Data Protection Regulation (GDPR) is essential to maintaining patient trust. Unauthorized access or misuse of sensitive health information can lead to ethical violations and potential discrimination in employment or insurance coverage. The ethical implementation of AI in preventive healthcare requires robust data governance policies, patient consent mechanisms, and secure encryption methods to protect personal health records from breaches and unauthorized exploitation.

2.10.3 Regulatory Challenges

The integration of AI into preventive healthcare introduces a complex layer of regulatory considerations that directly impact implementation, scalability, and adoption. As AI-driven diagnostic tools continue to evolve, they must navigate a landscape shaped by stringent data protection laws, international standards, and clinical validation requirements. Regulatory compliance ensures that AI applications maintain safety, efficacy, and ethical integrity in clinical environments. However, differing regulations across countries, the dynamic nature of AI models, and challenges in standardization present significant barriers. The table 1 below outlines key regulatory challenges associated with deploying AI-powered healthcare solutions.

Table 1. Regulatory challenges

Regulatory Challenge	Description
Compliance with Healthcare Standards	AI-driven healthcare solutions must comply with established regulatory standards such as HIPAA (Health Insurance Portability and Accountability Act), GDPR (General Data Protection Regulation), and ISO 13485 (Medical Devices - Quality Management Systems). These regulations ensure data privacy, patient safety, and standardization in AI-driven diagnostics and preventive healthcare. (WHO 2023)
Data Privacy and Security	AI models rely on vast amounts of patient data, requiring strict adherence to privacy laws to prevent unauthorized access and breaches. Regulations such as GDPR mandate patient consent and data anonymization, but ensuring compliance across different jurisdictions remains a challenge. AI developers must integrate encryption and secure storage mechanisms while maintaining interoperability with existing healthcare systems. (Williamson & Prybutok 2024)
Approval and Certification of AI Models	AI-powered diagnostic tools require rigorous testing, validation, and regulatory approval before they can be deployed in clinical settings. Regulatory bodies such as the FDA (U.S.), EMA (Europe), and MHRA (UK) impose strict requirements for AI-based medical devices. The dynamic nature of AI models, which continuously learn and evolve, complicates regulatory approval processes.(WHO 2023)
Interoperability with Existing Systems	AI solutions must integrate seamlessly with electronic health records (EHRs) and other healthcare IT systems. However, the lack of standardized data formats and regulatory inconsistencies between countries create barriers to interoperability, limiting AI's widespread adoption. Compliance with FHIR (Fast Healthcare Interoperability Resources) and HL7 (Health Level Seven) standards is essential but challenging due to varying healthcare infrastructures. (Li et al. 2024)
Liability and Ethical Concerns	Determining accountability in AI-powered healthcare is complex. If an AI system makes an incorrect diagnosis, it remains unclear whether liability falls on the healthcare provider, AI developer, or regulatory body. Many regulatory

	frameworks lack clear guidelines on AI accountability, creating legal uncertainty. Addressing this requires collaboration between policymakers, AI developers, and healthcare professionals. (Mensah 2023)
Cross-Border Regulatory Differences	AI-powered healthcare solutions often operate globally, but compliance with multiple regulatory frameworks is challenging. For instance, GDPR prioritizes data protection, while HIPAA focuses on data sharing within healthcare providers. AI companies must navigate different compliance requirements when deploying AI solutions across regions. Harmonizing global regulatory frameworks would facilitate AI integration but remains a complex task. (Gatlin 2025)

2.11 The Role of Ultrasound in Reducing Health Inequalities

Ultrasound imaging, particularly echocardiography, is a critical diagnostic tool in cardiovascular medicine. It provides real-time visualization of heart structures, blood flow dynamics, and functional abnormalities. Doppler ultrasound enhances cardiovascular assessments by measuring blood velocity, identifying stenosis, and detecting vascular anomalies. Echocardiography is widely used for diagnosing conditions such as heart valve disorders, myocardial dysfunction, congenital heart defects, and pericardial diseases (Esmaeilzadeh et al. 2013).

A study by Frush et al. (2023) highlights the advantages of ultrasound in cardiovascular diagnostics, emphasizing its non-invasive nature, affordability, and accessibility. Unlike MRI or CT scans, which require contrast agents and radiation exposure, ultrasound is a safer alternative for repeated cardiovascular assessments. It plays a crucial role in heart failure management by evaluating ejection fraction, left ventricular hypertrophy, and diastolic dysfunction. Additionally, portable ultrasound devices have expanded diagnostic capabilities in remote and resource-limited settings, allowing for point-of-care cardiac evaluations without the need for specialized infrastructure.

Additionally, AI-integrated ultrasound technology is transforming healthcare accessibility in resource-limited settings by providing accurate, automated, and cost-effective diagnostic solutions. AI-powered ultrasound enhances the diagnostic capabilities of minimally trained healthcare workers by automating image interpretation and providing real-time decision support. Portable AI-assisted ultrasound devices are being deployed in rural and underserved regions to diagnose cardiovascular conditions, pregnancy-related complications, and infectious diseases such as tuberculosis. These tools help reduce dependency on highly specialized sonographers, making ultrasound diagnostics more accessible in low-resource settings. (Gao et al. 2023)

A study by Kim et al. (2024) highlights AI-enhanced point-of-care ultrasound (POCUS) systems, which leverage deep learning algorithms to analyze ultrasound images in real time. These systems provide automated cardiac function assessments, detect abnormalities such as valve dysfunction and myocardial infarction, and enhance diagnostic accuracy for clinicians with limited ultrasound experience. AI-powered portable ultrasound devices, such as Butterfly iQ and Philips Lumify, have been deployed in several low-income countries, significantly improving early disease detection and reducing diagnostic delays. AI-driven ultrasound solutions also play a critical role in maternal and fetal health in remote regions by enabling early detection of high-risk pregnancies. AI-enhanced image analysis ensures timely intervention and reduces maternal and neonatal mortality.

2.11.1 Case Study: Aiatella

Aiatella is a medical technology company based in Helsinki, Finland, specializing in AI-powered cardiovascular diagnostics (Helsinki smart region, 2025). The company focuses on transforming cardiovascular workflows by integrating artificial intelligence (AI) into medical imaging and diagnostic processes. Its AI-driven ultrasound technology enhances early disease detection, providing more precise and faster analyses to support preventive healthcare. Aiatella's innovations aim to streamline cardiovascular diagnostics, reducing the time required for assessments and improving the accuracy of disease detection.

Aiatella's AI-powered ultrasound solutions are particularly beneficial for scalable and affordable healthcare. By automating image interpretation, the technology reduces dependency on highly trained specialists, making advanced diagnostics more accessible in resource-limited settings. AI integration allows real-time analysis, supporting clinicians with decision-making and improving diagnostic consistency. Portable AI-driven ultrasound devices developed by Aiatella can be deployed in rural and underserved regions, ensuring equitable access to quality healthcare.

The scalability of Aiatella's solutions is evident in their adaptability across various healthcare settings, from primary care clinics to specialized cardiovascular centers. By reducing diagnostic costs and improving efficiency, Aiatella's AI-powered tools present a model for integrating cutting-edge technology into preventive medicine. This approach aligns with the growing demand for AI-driven, cost-effective healthcare solutions that improve patient outcomes while addressing global health disparities.

2.12 Summary of Literature Review

The literature review of the thesis highlights the transformative role of AI in preventive healthcare, particularly in cardiovascular diagnostics. It emphasizes how AI-driven predictive models, machine learning (ML), and deep learning (DL) algorithms enhance early detection, risk assessment, and

personalized treatment strategies. Traditional diagnostic methods, such as ECGs and echocardiograms, often fall short in detecting asymptomatic cardiovascular diseases (CVDs) at an early stage, leading to delayed interventions. AI, through automated image analysis, predictive modeling, and wearable technology integration, improves diagnostic accuracy, reduces human error, and ensures timely interventions. However, the adoption of AI in preventive healthcare faces technical, ethical, and regulatory challenges, including data privacy concerns, model interpretability, and integration into existing healthcare infrastructure. AI-driven business models are also explored, highlighting opportunities such as subscription-based AI diagnostic services, AI-enhanced telemedicine, and value-based care. The research aligns with the focus on AI-powered cardiovascular diagnostics by addressing challenges and opportunities for business adoption, particularly for companies like Aiatella, which specialize in AI-enhanced ultrasound technology. By tackling cost-effectiveness, scalability, and regulatory compliance, the study aims to contribute to the optimization of AI-driven preventive healthcare solutions and their broader implementation.

3 Empirical Part

3.1 Research Conduction

This research adopted a qualitative methodology to explore the challenges and opportunities associated with integrating AI-powered solutions into preventive cardiovascular healthcare. Given the exploratory nature of the study and its focus on in-depth insights, semi-structured interviews with industry experts were selected as the primary data collection method.

A purposive sampling strategy was employed to identify and select participants with specific expertise relevant to the research topic. Professionals from various sectors were interviewed. This approach ensured that the perspectives gathered were both informed and aligned with the core objectives of the study.

3.2 Research Methods Adopted

This study employed a secondary research approach, specifically through semi-structured interviews using open-ended questions. The decision to adopt this method was grounded in the exploratory nature of the research, which aims to investigate the challenges, opportunities, and business potential of AI-driven preventive healthcare solutions, particularly in the field of cardiovascular diagnostics.

Secondary research involved a thorough review of academic literature, reports, and recent case studies relevant to AI in healthcare, cardiovascular diagnostics, preventive medicine, and business models. This helped establish a theoretical foundation and guided the development of the interview questions. The insights gained from the literature review provided the basis for identifying research gaps and framing the key areas of inquiry.

To complement and validate the secondary findings, a qualitative technique was adopted, involving semi-structured interviews with relevant professionals and experts in fields. The interview questions were open-ended and directly derived from the themes emerging in the literature review, ensuring coherence between theoretical insights and practical experiences.

The significance of choosing a qualitative method lies in its ability to capture in-depth perspectives, nuanced experiences, and real-world challenges that are often overlooked in quantitative approaches. Semi-structured interviews provided the flexibility to explore specific topics in detail while allowing participants the freedom to elaborate on areas they considered important. This approach is especially suitable for investigating emerging technologies like AI, where standardised measurements may not fully capture the complexities of implementation, adoption, and ethical considerations. Furthermore, the use of purposive sampling ensured that the selected participants had the relevant

knowledge and practical experience to contribute valuable insights, thus enhancing the credibility and relevance of the data collected.

3.3 Data Collection Process

To collect qualitative data aligned with the research objectives, a purposive sampling technique was used to select participants with relevant knowledge and professional experience in healthcare, artificial intelligence, and cardiovascular diagnostics. A total of five individuals were identified and invited to participate based on their direct involvement in areas such as cardiology, AI healthcare innovation, digital diagnostics, and medical device development. Their professional experience ranged from 5 to over 15 years, ensuring that insights were grounded in practical expertise.

The participants included clinical specialists, researchers, AI entrepreneurs, and digital health strategists. Some were engaged through the CURATE Bootcamp network, an international AI innovation program held at the Technical University of Košice, which brought together over 70 participants from five European universities. The bootcamp provided hands-on training in AI-driven problem solving and served as a valuable networking platform. During the event, the researcher conducted two interviews, one with a PhD-level medical AI researcher and another with a founder of a medical AI startup, both of whom offered critical perspectives on ethical challenges and AI implementation in healthcare.

Additional participants were approached through a professional referral by the CEO of Aiatella, who facilitated contact with three high-profile healthcare professionals in cardiology and medical education. This method of networking ensured access to qualified experts willing to contribute substantive insights to the study.

Two cardiologist were conducted physically by the researcher and for rest data was collected using a semi-structured interview questionnaire developed in a Microsoft Word document. The questions were derived from themes identified in the literature review and designed to be open-ended to encourage comprehensive, narrative responses. Each participant received the questionnaire via email along with a brief explanation of the research purpose and instructions for completion. The estimated response time was approximately 30 minutes, and participants were given a one-week window to respond at their convenience.

All participants returned their completed questionnaires within the specified time frame. Several participants noted that this asynchronous format was significantly more convenient than scheduling a live interview, given their demanding schedules and clinical responsibilities. The document-based format allowed them to reflect on each question and respond thoroughly without the pressure of a

real-time conversation. This flexible approach proved both efficient and respectful of participants' professional commitments, enhancing response quality and participation rate.

3.4 Data Analysis Method

The collected data from the semi-structured interview questionnaires were analyzed using manual thematic analysis, a widely recognized method in qualitative research for identifying, analyzing, and interpreting patterns of meaning within textual data. This approach was chosen for its flexibility and suitability in exploring complex, subjective experiences and perspectives, particularly in emerging fields like AI in preventive cardiovascular healthcare. Thematic analysis process Braun and Clarke is defined as

- Familiarize yourself with the data by reading it thoroughly and noting initial ideas.
- Generate initial codes by systematically identifying key features across the dataset.
- Organize related codes into potential themes that capture broader patterns.
- Review and refine themes to ensure they accurately represent the data.
- Define and name each theme clearly to reflect its core meaning.
- Compile the final analysis with supporting evidence and relate it to the research objectives.
- To systematically manage and organize the data, Microsoft Excel was used.

Each participant's responses were entered into a structured spreadsheet format, with individual sheets created for each interview. Initial reading of the responses allowed for familiarization with the data, after which open coding was conducted. Key phrases, concepts, and recurring ideas were highlighted and tagged with preliminary codes directly in Excel.

Following the initial coding, similar codes were grouped together to form themes and sub-themes, which aligned with the research objectives and the theoretical framework derived from the literature review. This process involved iterative refinement to ensure that the themes accurately reflected the participants' insights and captured the depth and diversity of perspectives.

Manual thematic analysis allowed the researcher to remain closely engaged with the data, preserving contextual meaning and ensuring a nuanced interpretation of findings. Excel provided an effective and accessible platform for organizing data, tracking coding decisions, and visually mapping relationships between themes.

4 Results and Findings

This study examines the key business challenges and opportunities in adopting AI-driven preventive healthcare solutions for cardiovascular diagnostics. Through thematic analysis of interview data, the research identifies barriers such as clinical skepticism, data privacy concerns, and integration issues, while also highlighting opportunities in AI-powered diagnostic imaging, risk prediction, and remote monitoring. These findings provide insights into both the challenges and transformative potential of AI in improving cardiovascular care.

4.1 Demographic Information

Table 2. Demographic profile

S.No	Gender	Professional Experience / Education	Profession
P(1)	Male	Cardiology, Master's in Public Health (Johns Hopkins University), Founder & CEO	Cardiologist, Founder & CEO
P(2)	Male	Director of Pediatric Electrophysiology	Pediatric Electrophysiologist
P(3)	Female	PhD in Medical AI, 5+ years of experience in Medical AI research	Medical AI Researcher
P(4)	Female	Founder of a Medical AI startup, Master's in AI	Medical AI Startup Founder
P(5)	Male	10+ years of experience in Healthcare AI, Founder & CEO	Healthcare AI Solutions Founder & CEO

4.2 Thematic Analysis

4.2.1 Generate Initial Codes Based on the Interview Data

To conduct thematic analysis, this step involves assigning initial codes to relevant segments of the interview data. These codes help to identify significant statements that are closely related to the core themes of the research, such as the challenges of AI adoption, early detection and diagnostics, and business opportunities in healthcare. Below, is presented the detailed open coding process with examples and tables summarizing the key themes and codes derived from the interview responses.

Interview Question 1: What do you see as the biggest challenges in adopting AI-driven preventive healthcare solutions for cardiovascular diagnostics in the current healthcare system?

Participants identified challenges such as **product-solution fit**, **market penetration**, and overcoming **clinical skepticism** as key barriers to adopting AI in healthcare.

Interview Excerpt	Initial Code
"The challenge is achieving product-solution fit and convincing the market that the solution is effective and valuable. It's also about penetrating existing hospital IT ecosystems dominated by large vendors like Siemens, Philips, and GE." (P1)	Product-Solution Fit, Market Penetration
"From a clinical side, convincing doctors that AI tools are superior to current diagnostic methods is the biggest challenge. There's skepticism due to past failures with unreliable ECG machine interpretations." (P2)	Clinical Skepticism, Adoption by Clinicians
"AI models require large, high-quality datasets to be accurate, and data privacy and ethical concerns are prominent. Regulatory approval processes are also slow and challenging." (P3)	Data Privacy, Regulatory Challenges
"AI faces challenges due to inconsistent data formats, and clinicians are skeptical, especially regarding AI decision-making transparency." (P5)	Data Inconsistency, Transparency Concerns

Interview Question 2: How do you think AI-powered diagnostics, such as machine learning and deep learning models, can improve early detection and risk assessment in cardiovascular diseases?

The main potential for AI-powered diagnostics lies in **early detection**, **hidden pattern identification**, and the ability to process **real-time data from wearables** for proactive intervention.

Interview Excerpt	Initial Code
"AI has the potential to analyze ultrasound data and build 3D models of the aorta, enabling earlier detection, but the key is proving that it improves patient outcomes." (P1)	Early Detection, Proving Improved Outcomes

"AI can identify syndromes like Long QT from large ECG datasets. However, it needs to prove that early detection leads to real clinical benefits like improved quality of life or survival." (P2)	Clinical Benefit, Evidence for Impact
"AI can identify hidden patterns in ECGs and imaging data that humans may miss, offering a chance for earlier intervention, especially for conditions like plaques." (P3)	Hidden Patterns, Early Intervention
"AI can process real-time data from wearables and spot high-risk issues like heart failure exacerbations, offering earlier intervention opportunities." (P4)	Wearable Tech, Real-time Monitoring

Interview Question 3: From a business perspective, what are the key factors that could drive or hinder the scalability and affordability of AI-driven cardiovascular diagnostic solutions?

Key factors driving or hindering scalability include **market competition**, **cloud usage for cost reduction**, and the integration of AI tools into existing **clinical workflows**.

Interview Excerpt	Initial Code
"Competition from established companies and convincing providers about the real value of AI in healthcare. Integration into existing hospital systems is another major barrier." (P1)	Market Competition, Integration Challenges
"Cost-effectiveness must be proven, and AI must show measurable benefits both individually and systemically for adoption. There's also skepticism from insurers or governments." (P2)	Cost-Effectiveness, Skepticism
"Scalability depends on cloud usage, which can reduce costs and enable remote updates. Once regulatory approval is granted, it becomes easier to scale and integrate into existing systems." (P3)	Cloud Usage, Scalability
"Key factors include integration with clinical workflows, collaboration to bring in capital, and creating distribution networks for accelerated market access." (Respondent 4)	Workflow Integration, Capital Collaboration

Interview Question 4: What role do regulatory and ethical concerns, such as data privacy and AI transparency, play in the adoption of AI in preventive healthcare?

Regulatory and ethical concerns such as **compliance with HIPAA, data privacy**, and **transparency** in AI decision-making are crucial to successful AI adoption.

Interview Excerpt	Initial Code
"AI tools must meet strict compliance like HIPAA, and lengthy regulatory processes slow down implementation. Many AI tools are still in research because they are not ready for prime time." (P1)	Compliance, Regulatory Hurdles
"Data privacy and ethics are huge concerns, especially in pediatrics. AI must be regulated properly to ensure clinical safety and legal compliance." (P2)	Data Privacy, Pediatric Concerns
"Data privacy, transparency, and regulatory approvals are crucial. AI must comply with standards like FDA and EMA for credibility, but regulators are hesitant about adaptive models that evolve over time." (P3)	Transparency, Adaptive Models
"AI in Healthcare is considered as a medical device by the FDA and EMA, so it's held to the same standards for clinical effectiveness and safety." (P5)	Medical Device Standards, Clinical Effectiveness

Interview Question 5: In your opinion, what are the most promising business opportunities that AI can offer in preventive cardiovascular healthcare?

Diagnostic imaging, preventive screening, and AI-powered risk prediction platforms are seen as the most promising business opportunities in AI-driven cardiovascular healthcare.

Interview Excerpt	Initial Code
"Tools that automate diagnostic imaging like aortic ultrasounds and support rural and low-resource settings are some of the high-value AI-driven opportunities in preventive cardiovascular healthcare." (P1)	Diagnostic Imaging, Rural Healthcare
"AI could help identify high-risk individuals earlier, reducing long-term healthcare costs and resource use." (P2)	Risk Identification, Cost Reduction
"AI-powered risk prediction platforms for B2B and B2G markets are promising. These can integrate with EHRs to flag high-risk issues, driving early intervention and cost-saving in healthcare." (P3)	B2B/B2G Platforms, Early Intervention

"Public health and preventive screening could be huge wins for AI, especially in underserved populations. AI can enable quicker screenings of large datasets, reducing hospital burdens." (P4)	Preventive Screening, Public Health
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------

4.3 Search for Themes

This section reflects the themes derived from the interview data, focusing on the business challenges and opportunities surrounding AI in cardiovascular diagnostics. The themes explore the barriers such as clinical skepticism, data privacy concerns, and system integration, along with the promising opportunities like AI-powered diagnostic imaging, risk prediction platforms, and remote monitoring. These themes provide valuable insights into the factors influencing the adoption and scalability of AI-driven healthcare solutions.

Table 3. Combined Table of Themes, Sub-Themes, Codes, and Example Quotes

Theme	Sub-Theme	Codes	Example Quotes
Key Business Challenges	Product-Solution Fit	Product-Solution Fit, Market Penetration	"The challenge is achieving product-solution fit and convincing the market..." (P1)
	Clinical Skepticism	Adoption by Clinicians, Skepticism	"Convincing doctors that AI tools are superior to current diagnostic methods..." (P2)
	Data Privacy and Security	Data Privacy, Ethical Concerns, Regulatory Hurdles	"AI models require large, high-quality datasets...and data privacy is a concern." (P3)
	Integration into Healthcare Systems	Interoperability, Legacy Systems, Workflow Integration	"Integration into existing hospital systems is another major barrier." (P1)
Business Opportunities	Diagnostic Imaging	Automated Imaging, AI for Diagnostics	"AI-powered tools for diagnostic imaging like aortic ultrasounds are high-value opportunities..." (P1)

	Risk Prediction Platforms	B2B/B2G Platforms, Early Intervention	"AI-powered risk prediction platforms for B2B and B2G markets are promising..." (P3)
	Remote Monitoring and Wearables	Wearable Tech, Real-time Monitoring	"Wearable devices can track heart rate variability, detect arrhythmias, and monitor blood pressure in real time..." (P4)
	Preventive Screening	Population Health, Public Health, Early Detection	"AI can enable quicker screenings of large datasets, reducing hospital burdens..." (P4)

Key Business Challenges in AI-Driven Preventive Healthcare

In AI-driven preventive healthcare, the primary business challenges revolve around product-solution fit, clinical skepticism, and data privacy and integration concerns. Participants emphasized that achieving a clear product-solution fit, where AI tools meet the specific needs of the healthcare market, is crucial for adoption. The challenge of penetrating existing hospital IT ecosystems, dominated by large players like Siemens, Philips, and GE, was highlighted as a significant barrier. For instance, one participant stated, "The challenge is achieving product-solution fit and convincing the market that the solution is effective and valuable." Additionally, clinical skepticism remains a roadblock, with many healthcare professionals hesitant to trust AI tools over traditional diagnostic methods, particularly due to past failures with unreliable ECG machine interpretations. One participant shared, "Convincing doctors that AI tools are superior to current diagnostic methods is the biggest challenge." This underscores the need for clinicians to see tangible value in AI to embrace it fully.

Moreover, data privacy concerns and system integration challenges were frequently noted. With AI models requiring large datasets to function effectively, ensuring the security and privacy of sensitive health information remains a critical issue. One participant remarked, "AI models require large, high-quality datasets...and data privacy is a concern." The integration of AI solutions into existing healthcare systems, especially with legacy IT infrastructures, was also a significant hurdle. This process often involves overcoming technical difficulties related to data compatibility and ensuring seamless interoperability with electronic health records (EHRs). Such barriers are compounded by regulatory challenges, where compliance with standards like HIPAA and GDPR is essential yet complex, and delays in regulatory approval slow down the implementation of AI-driven tools.

Business Opportunities in AI-Driven Preventive Healthcare

In terms of business opportunities, the integration of AI-powered diagnostic imaging, risk prediction platforms, and remote monitoring technologies offers significant potential for the transformation of cardiovascular healthcare. Participants noted that AI-driven diagnostic imaging tools, like automated ultrasound analyses, have the potential to make cardiovascular diagnostics faster, more accurate, and widely accessible. One participant highlighted, "Tools that automate diagnostic imaging like aortic ultrasounds are high-value opportunities in preventive cardiovascular healthcare." These advancements are not only expected to improve diagnostic precision but also make healthcare more accessible, particularly in rural and low-resource settings.

Another promising business opportunity lies in the development of AI-powered risk prediction platforms, which can help healthcare providers identify high-risk individuals earlier and enable timely interventions. These platforms, often integrated with electronic health records (EHRs), allow for personalized risk assessments based on an individual's medical history, lifestyle, and genetic data. Additionally, AI-driven remote monitoring technologies, such as wearable devices that track heart rate variability and blood pressure, are revolutionizing preventive healthcare. One respondent pointed out, "Wearable devices can track heart rate variability, detect arrhythmias, and monitor blood pressure in real time," which enables proactive management of cardiovascular health and reduces the burden on healthcare facilities. These opportunities collectively point to a future where AI enhances early detection, continuous monitoring, and personalized care, driving both business growth and improved patient outcomes.

5 Discussion

This study examined the key business challenges and opportunities in the adoption of AI-driven preventive healthcare solutions for cardiovascular diagnostics. Through thematic analysis of interview data, we identified various barriers to adoption, including clinical skepticism, market penetration, data privacy concerns, and integration with existing healthcare systems. Conversely, we also highlighted significant business opportunities in AI-powered diagnostic imaging, risk prediction platforms, and remote monitoring. In the following sections, each finding will be discussed in detail with reference to the existing literature.

5.1 Key Business Challenges

5.1.1 Clinical Skepticism and Trust in AI Solutions

A major barrier to the adoption of AI in cardiovascular healthcare is clinical skepticism. Healthcare professionals are often hesitant to embrace AI solutions due to trust issues, particularly regarding the reliability and accuracy of AI systems compared to traditional diagnostic tools. One participant noted, "Convincing doctors that AI tools are superior to current diagnostic methods is the biggest challenge." This finding aligns with previous research that suggests the success of AI in healthcare largely depends on clinician acceptance. For example, a study by Rajeev & Natarajan (2025) emphasized that AI adoption in healthcare is heavily dependent on the validation of AI systems by clinicians. Furthermore, clinical skepticism has been identified as a primary barrier in several studies (Kumar Das et al. 2024), with clinicians often requiring extensive evidence of AI's clinical efficacy and its ability to outperform existing diagnostic methods.

5.1.2 Product-Solution Fit and Market Penetration

Another significant challenge identified in the interviews was the issue of product-solution fit and market penetration. Participants highlighted that AI solutions must be tailored to meet the specific needs of healthcare providers and demonstrate their value in improving patient outcomes. One respondent mentioned, "The challenge is achieving product-solution fit and convincing the market that the solution is effective and valuable." This sentiment echoes the findings of Ahmed et al. (2023), who found that market penetration for new AI healthcare solutions is often hindered by competition from established healthcare vendors and reluctance from hospitals to switch to newer, unproven technologies. Additionally, Vaghefi et al. (2022) emphasized the difficulty in penetrating the healthcare market due to the entrenched presence of large healthcare IT firms like Siemens and Philips, which dominate hospital infrastructures.

5.1.3 Data Privacy and Integration Issues

The third major barrier identified was the challenge of data privacy and the difficulty in integrating AI systems into existing healthcare infrastructures. AI systems require vast amounts of patient data for accurate predictions, yet the collection, storage, and sharing of such data are governed by strict regulations such as HIPAA and GDPR. One participant commented, "AI models require large, high-quality datasets...and data privacy is a concern." This finding is consistent with previous studies (Abdollahi et al. 2024), which highlight data privacy and security concerns as significant obstacles to the adoption of AI in healthcare. Furthermore, integration issues are compounded by the complex, legacy IT systems present in most hospitals, which often lack compatibility with newer AI technologies (Rajeev & Natarajan 2025).

5.2 Business Opportunities in AI-Driven Preventive Healthcare

Despite these challenges, our study also uncovered several promising business opportunities in AI-driven preventive healthcare, particularly in diagnostic imaging, risk prediction platforms, and remote monitoring technologies. These opportunities have the potential to address some of the most pressing issues in cardiovascular healthcare, such as early detection, real-time monitoring, and accessibility in underserved regions.

5.2.1 AI-Powered Diagnostic Imaging

One of the most promising opportunities in the AI space is AI-powered diagnostic imaging, particularly for cardiovascular conditions like aortic diseases. Participants emphasized that AI tools capable of automating diagnostic imaging can enhance the speed and accuracy of diagnoses, especially in rural or low-resource settings. One participant stated, "Tools that automate diagnostic imaging like aortic ultrasounds are high-value opportunities." This opportunity is supported by the literature, as studies by Vaghefi et al. (2022) and Ahmed et al. (2023) have demonstrated that AI in diagnostic imaging can significantly improve diagnostic accuracy, reduce human error, and increase access to timely diagnoses. In addition, AI has been shown to be especially effective in areas like radiology, where deep learning algorithms can detect abnormalities such as plaques in the aorta, which might otherwise go unnoticed by human practitioners (Kumar Das et al. 2024).

5.2.2 AI for Risk Prediction and Early Intervention

Another critical opportunity lies in AI-powered risk prediction platforms. These platforms enable healthcare providers to assess patient risks using data from electronic health records (EHRs), genetic data, and lifestyle information. Participants identified that these tools could lead to earlier intervention and better management of cardiovascular diseases, potentially reducing long-term

healthcare costs. One respondent remarked, "AI-powered risk prediction platforms for B2B and B2G markets are promising...These can integrate with EHRs to flag high-risk issues, driving early intervention and cost-saving in healthcare." This is consistent with findings in the literature, where studies like those by Rajeev & Natarajan (2025) and Vaghefi et al. (2022) emphasize the importance of AI in risk prediction, particularly in preventive healthcare. The ability to predict and intervene early has the potential to significantly reduce morbidity and mortality associated with cardiovascular diseases.

5.2.3 Wearables and Remote Monitoring

AI's role in remote monitoring through wearable technologies also presents a significant business opportunity. Participants discussed the potential of wearables that monitor vital signs like blood pressure, heart rate, and ECG in real-time, which allows for continuous monitoring and proactive management of cardiovascular health. One participant stated, "Wearable devices can track heart rate variability, detect arrhythmias, and monitor blood pressure in real time." The literature supports this, with studies indicating that AI-powered wearable devices are increasingly being integrated into healthcare systems to provide continuous patient monitoring, improve chronic disease management, and reduce hospital readmissions (Abdollahi et al. 2024).

5.2.4 Scalability and Integration into Value-Based Care

In terms of business models, the findings also highlighted the potential of value-based care models that are compatible with AI technologies. AI can help healthcare providers move from a fee-for-service model to a value-based system where the focus is on patient outcomes rather than the volume of services provided. As Vaghefi et al. (2022) pointed out, AI's ability to integrate into existing EHRs and monitor patient health in real time can provide the necessary data to support this transition. Furthermore, AI-driven platforms that integrate predictive analytics can assist in reducing healthcare costs while improving patient care, making them attractive to both businesses and healthcare providers.

6 Conclusion and Future Work

This study aimed to explore the key business challenges and opportunities surrounding the adoption of AI-driven preventive healthcare solutions in cardiovascular diagnostics. The findings from the thematic analysis revealed several significant challenges to the widespread adoption of AI technologies. Clinical skepticism emerged as a major barrier, with healthcare professionals often hesitant to trust AI systems over traditional diagnostic methods. The reluctance stems from concerns over the reliability and accuracy of AI tools, which underscores the need for more robust clinical validation. In addition, market penetration posed a challenge, with the dominance of established healthcare vendors like Siemens and Philips making it difficult for new AI solutions to break into the market. Furthermore, data privacy concerns and the integration of AI systems into existing healthcare infrastructures were highlighted as additional hurdles. These issues relate to the need for AI systems to be compliant with strict regulatory requirements and to function seamlessly within the complex IT systems already in place in healthcare facilities. Despite these challenges, the study also highlighted promising business opportunities for AI in preventive cardiovascular healthcare. AI-powered diagnostic imaging solutions, such as automated aortic ultrasounds, can improve diagnostic accuracy and accessibility, particularly in low-resource settings. Risk prediction platforms, leveraging AI to assess patient risk profiles, can enable earlier interventions and reduce long-term healthcare costs. Moreover, remote monitoring technologies powered by AI are poised to enhance continuous patient monitoring, improving chronic disease management and early detection of cardiovascular events. These findings align with the growing body of literature emphasizing the transformative potential of AI in healthcare, particularly for improving patient outcomes and operational efficiency.

The opportunities identified in this study point to the considerable potential for AI in revolutionizing cardiovascular diagnostics and preventive healthcare. However, to fully capitalize on these opportunities, several factors need to be addressed. First, the successful integration of AI tools into existing healthcare systems requires overcoming technical challenges related to interoperability and data sharing. AI solutions must be able to communicate effectively with electronic health records (EHRs) and other clinical tools. Furthermore, the regulatory landscape for AI in healthcare must evolve to ensure that AI tools meet stringent safety and efficacy standards while protecting patient privacy. The study also found that business models for AI in healthcare are increasingly shifting towards value-based care approaches, where AI tools can be leveraged to improve patient outcomes and reduce healthcare costs. In this context, AI's role in early detection, personalized treatment, and chronic disease management is expected to grow, providing significant economic benefits to both healthcare providers and patients. However, for AI to be widely adopted, the healthcare industry must address the barriers of clinical trust, data security, and system integration, while also exploring new business models that can make AI-driven healthcare solutions more accessible and affordable.

Overall, the findings suggest that AI has the potential to significantly improve cardiovascular care, but its successful integration will depend on overcoming the identified challenges.

6.1 Research Limitations

- The study's findings are based on interviews conducted with professionals primarily within specific healthcare markets, limiting the generalizability of the results to other regions with different healthcare structures and regulatory environments.
- The sample size of interview participants was relatively small, and the views expressed may not fully represent the broader healthcare community or all stakeholders involved in the adoption of AI in healthcare.

6.2 Future Work

- Future research should explore AI adoption in diverse healthcare systems across different regions to examine how geographical and regulatory factors influence AI integration.
- Conducting longitudinal studies would help assess the long-term effects of AI tools on cardiovascular outcomes, patient care, and healthcare costs.
- Future research should include a wider range of stakeholders, such as healthcare providers, patients, and AI developers, to capture a more comprehensive view of the challenges and opportunities related to AI in cardiovascular healthcare.

Sources

- Abdollahi, M., Jafarizadeh, A., Ghafouri-Asbagh, A., Sobhi, N., Pourmoghtader, K., Pedrammehr, S., Asadi, H., Tan, R., Alizadehsani, R., & Acharya, U. R. (2024). Artificial intelligence in assessing cardiovascular diseases and risk factors via retinal fundus images: A review of the last decade. *WIREs Data Mining and Knowledge Discovery*, 14(6). <https://doi.org/10.1002/widm.1560>
- Ahmed, M. I., Spooner, B., Isherwood, J., Lane, M. A., Orrock, E., & Dennison, A. (2023). A Systematic Review of the Barriers to the Implementation of Artificial Intelligence in Healthcare. *Cureus*, 15(10). <https://doi.org/10.7759/cureus.46454>
- Almansouri, N. E., Awe, M., Selvambigay Rajavelu, Kudapa Jahnvi, Shastry, R., Hasan, A., Hasan, H., Mohit Lakkimsetti, Reem Khalid AlAbbasi, Brian Criollo Gutiérrez, & Haider, A. (2024). Early Diagnosis of Cardiovascular Diseases in the Era of Artificial Intelligence: An In-Depth Review. *Curēus*. <https://doi.org/10.7759/cureus.55869>
- Alsadoun, L., Ali, H., Mushtaq, M. M., Mushtaq, M., Burhanuddin, M., Anwar, R., Maryyam Liaqat, Syed, Hasan, A. H., & Ahmed, F. (2024). Artificial Intelligence (AI)-Enhanced Detection of Diabetic Retinopathy From Fundus Images: The Current Landscape and Future Directions. *Cureus*. <https://doi.org/10.7759/cureus.67844>
- Ansari, Y., Abou, O., Qaraqe, K. A., & Erchin Serpedin. (2023). Deep learning for ECG Arrhythmia detection and classification: an overview of progress for period 2017–2023. *Frontiers in Physiology*, 14. <https://doi.org/10.3389/fphys.2023.1246746>
- Arnould, L., Fabrice Mériaudeau, Guenancia, C., Clément Germanèse, Delcourt, C., Kawasaki, R., Cheung, C. Y., Creuzot-Garcher, C., & Grzybowski, A. (2022). Using Artificial Intelligence to Analyse the Retinal Vascular Network: The Future of Cardiovascular Risk Assessment Based on Oculomics? A Narrative Review. *Ophthalmology and Therapy*, 12(2), 657–674. <https://doi.org/10.1007/s40123-022-00641-5>
- Baklola, M., & Terra, M. (2024). AI-Powered Predictive Analytics for Crowd Health Management. *Mass Gathering Medicine*, 100009. <https://doi.org/10.1016/j.mgmed.2024.100009>
- Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., Delling, F. N., Djousse, L., Elkind, M. S. V., Ferguson, J. F., Fornage, M., Jordan, L. C., Khan, S. S., Kissela, B. M., Knutson, K. L., & Kwan,

T. W. (2019). Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. *Circulation*, 139(10), 56–528. <https://doi.org/10.1161/cir.0000000000000659>

Bhandari, A. (2024). Revolutionizing Radiology With Artificial Intelligence. *Cureus*, 16(10). <https://doi.org/10.7759/cureus.72646>

Bikash Behera, Irshad, A., Rida, I., & Shabaz, M. (2025). AI-Driven Predictive Modeling for Disease Prevention and Early Detection. *SLAS TECHNOLOGY*, 100263–100263. <https://doi.org/10.1016/j.slast.2025.100263>

Blanco-González, A., Cabezón, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & Garcia-Fandino, R. (2023). The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. *The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies*, 16(6), 891–891. <https://doi.org/10.3390/ph16060891>

Carrington, M., Providência, R., Chahal, C. A. A., Ricci, F., Epstein, A. E., Gallina, S., Fedorowski, A., Sutton, R., & Khanji, M. Y. (2022). Monitoring and Diagnosis of Intermittent arrhythmias: evidence-based Guidance and Role of Novel Monitoring Strategies. *European Heart Journal Open*, 2(6). <https://doi.org/10.1093/ehjopen/oeac072>

Chen, C., Qin, C., Qiu, H., Tarroni, G., Duan, J., Bai, W., & Rueckert, D. (2020). Deep Learning for Cardiac Image Segmentation: A Review. *Frontiers in Cardiovascular Medicine*, 7. <https://doi.org/10.3389/fcvm.2020.00025>

Chumachenko, D., & Yakovlev, S. (2025). Artificial Intelligence Applications in Public Health. *Computation*, 13(2), 53. <https://doi.org/10.3390/computation13020053>

Connors, K. M., Avery, C. L., & Syed, F. F. (2024). Advancing Cardiovascular Risk Assessment with Artificial Intelligence: Opportunities and Implications in North Carolina. *North Carolina Medical Journal*, 85(1). <https://doi.org/10.18043/001c.91424>

Deon, L., & Jackson, M. (2025). Logistic Regression and Beyond: AIDriven Models for Predicting Heart Disease in EHealthcare. <https://doi.org/10.13140/RG.2.2.11869.93928>

Dixon, D., Sattar, H., Moros, N., Kesireddy, S. R., Ahsan, H., Lakkimsetti, M., Fatima, M., Doshi, D., Sadhu, K., & Hassan, M. J. (2024). Unveiling the Influence of AI Predictive Analytics on Patient Outcomes: A Comprehensive Narrative Review. *Cureus*, 16(5). <https://doi.org/10.7759/cureus.59954>

- Esmailzadeh, M., Mozghan Parsaee, & Maleki, M. (2013). The Role of Echocardiography in Coronary Artery Disease and Acute Myocardial Infarction. *The Journal of Tehran University Heart Center*, 8(1), 1. <https://pmc.ncbi.nlm.nih.gov/articles/PMC3587668/>
- Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., Cui, C., Corrado, G., Thrun, S., & Dean, J. (2019). A Guide to Deep Learning in Healthcare. *Nature Medicine*, 25(1), 24–29. <https://doi.org/10.1038/s41591-018-0316-z>
- Eze-Nliam, C. M., Zhang, Z., Weiss, S. A., & Weintraub, W. S. (2014). Cost-effectiveness assessment of cardiac interventions: determining a socially acceptable cost threshold. *Interventional Cardiology*, 6(1), 45–55. <https://doi.org/10.2217/ica.13.81>
- Fahim, S., & Fahim, S. (2024, September 20). Preventive Health Measures: The Key to Reducing Healthcare Costs | Valparaiso University. Valparaiso University. <https://onlinedegrees.valpo.edu/reducing-healthcare-costs-with-preventative-health-measures/>
- Fosso Wamba, S., Akter, S., Edwards, A., Chopin, G., & Gnanzou, D. (2019). How “big data” can make big impact: Findings from a systematic review and a longitudinal case study. *International Journal of Production Economics*, 165(165), 234–246. <https://doi.org/10.1016/j.ijpe.2014.12.031>
- Frush, D. P., Callahan, M. J., Coley, B. D., Nadel, H. R., & R Paul Guillerman. (2023). Comparison of the different imaging modalities used to image pediatric oncology patients: A COG diagnostic imaging committee/SPR oncology committee white paper. 70(S4). <https://doi.org/10.1002/pbc.30298>
- Gao, X., Qi Lv, & Hou, S. (2023). Progress in the Application of Portable Ultrasound Combined with Artificial Intelligence in Pre-Hospital Emergency and Disaster Sites. *Diagnostics*, 13(21), 3388–3388. <https://doi.org/10.3390/diagnostics13213388>
- Gatlin, H. (2025). AI Compliance in Healthcare — What Providers Need to Know. *TheSuperbill.com*. <https://www.thesuperbill.com/blog/ai-compliance-in-healthcare-what-providers-need-to-know-about-security-regulations>
- Gerke, S., Minssen, T., & Cohen, G. (2020). Ethical and Legal Challenges of Artificial intelligence-driven Healthcare. *Artificial Intelligence in Healthcare*, 1(1), 295–336. <https://doi.org/10.1016/B978-0-12-818438-7.00012-5>
- Ghodeswar, G. K., Dube, A., & Khobragade, D. (2023). Impact of lifestyle modifications on cardiovascular health: A narrative review. *Cureus*, 15(7). <https://doi.org/10.7759/cureus.42616>

- Gruson, D., Fux, E., Kemalöglu Öz, T., Gouget, B., Lee, W., Shah, S., Liu, Y., Ebert, S., Greaves, R., Bernardini, S., Yang, H. S., & Figueroa Montes, L. (2024). Contribution of laboratory medicine and emerging technologies to cardiovascular risk reduction via exposome analysis: an opinion of the IFCC Division on Emerging Technologies. *Clinical Chemistry and Laboratory Medicine (CCLM)*. <https://doi.org/10.1515/cclm-2024-0788>
- Jafari, M., Shoeibi, A., Khodatars, M., Ghassemi, N., Moridian, P., Alizadehsani, R., Khosravi, A., Ling, S. H., Delfan, N., Zhang, Y.-D., Wang, S.-H., Gorriz, J. M., Alinejad-Rokny, H., & Acharya, U. R. (2023). Automated diagnosis of cardiovascular diseases from cardiac magnetic resonance imaging using deep learning models: A review. *Computers in Biology and Medicine*, 160, 106998. <https://doi.org/10.1016/j.compbiomed.2023.106998>
- Kalogiannidis, S., Kalfas, D., Papaevangelou, O., Giannarakis, G., & Chatzitheodoridis, F. (2024). The Role of Artificial Intelligence Technology in Predictive Risk Assessment for Business Continuity: A Case Study of Greece. *Risks*, 12(2), 19–19. MDPI. <https://www.mdpi.com/2227-9091/12/2/19>
- Kaminsky, L. A., German, C., Imboden, M., Ozemek, C., Peterman, J. E., & Brubaker, P. H. (2021). The importance of healthy lifestyle behaviors in the prevention of cardiovascular disease. *Progress in Cardiovascular Diseases*, 70(0033-0620), 8–15. <https://doi.org/10.1016/j.pcad.2021.12.001>
- Kim, S., Fischetti, C., Guy, M., Hsu, E., Fox, J., & Young, S. D. (2024). Artificial Intelligence (AI) Applications for Point of Care Ultrasound (POCUS) in Low-Resource Settings: A Scoping Review. *Diagnostics*, 14(15), 1669–1669. <https://doi.org/10.3390/diagnostics14151669>
- Knudsen, J. E., Ghaffar, U., Ma, R., & Hung, A. J. (2024). Clinical applications of artificial intelligence in robotic surgery. *Journal of Robotic Surgery*, 18(1). <https://doi.org/10.1007/s11701-024-01867-0>
- Kumar Das, S., Kumari Dasgupta, R., Deb Roy, S., & Shil, D. (2024). AI in Indian healthcare: From roadmap to reality. *Intelligent Pharmacy*. <https://doi.org/10.1016/j.ipha.2024.02.005>
- Leclerc, S., Smistad, E., Pedrosa, J., Ostvik, A., Cervenansky, F., Espinosa, F., Espeland, T., Berg, E. A. R., Jodoin, P.-M., Grenier, T., Lartizien, C., Dhooge, J., Lovstakken, L., & Bernard, O. (2019). Deep Learning for Segmentation Using an Open Large-Scale Dataset in 2D Echocardiography. *IEEE Transactions on Medical Imaging*, 38(9), 2198–2210. <https://doi.org/10.1109/tmi.2019.2900516>

- Li, Y.-H., Li, Y.-L., Wei, M.-Y., & Li, G.-Y. (2024). Innovation and challenges of artificial intelligence technology in personalized healthcare. *Scientific Reports*, 14(1). <https://doi.org/10.1038/s41598-024-70073-7>
- Litjens, G., Kooi, T., Bejnordi, B. E., Setio, A. A. A., Ciompi, F., Ghafoorian, M., van der Laak, J. A. W. M., van Ginneken, B., & Sánchez, C. I. (2017). A Survey on Deep Learning in Medical Image Analysis. *Medical Image Analysis*, 42(1), 60–88. <https://doi.org/10.1016/j.media.2017.07.005>
- Luo, Y., Liu, J., Zeng, J., & Pan, H. (2024). Global burden of cardiovascular diseases attributed to low physical activity: An analysis of 204 countries and territories between 1990 and 2019. *American Journal of Preventive Cardiology*, 17, 100633–100633. <https://doi.org/10.1016/j.ajpc.2024.100633>
- Marey, A., Parisa Arjmand, Sabe, D., Mohammad Javad Eslami, Saad, A. M., Sanchez, N., & Muhammad Umair. (2024). Explainability, transparency and black box challenges of AI in radiology: impact on patient care in cardiovascular radiology. *The Egyptian Journal of Radiology and Nuclear Medicine*, 55(1). <https://doi.org/10.1186/s43055-024-01356-2>
- Mbanugo, O. J. (2025). AI-enhanced telemedicine: A common-sense approach to chronic disease management and a tool to bridging the gap in healthcare disparities. *International Journal of Research Publication and Reviews*, 6(2), 3223–3241. <https://doi.org/10.55248/gengpi.6.0225.0952>
- Mbanugo, O. J., & Unanah, O. V. (2025). AI-Driven TeleHealthcare: Business Models and Strategies for Addressing Healthcare Disparities. *International Journal of Computer Applications Technology and Research*. <https://doi.org/10.7753/ijcatr1402.1012>
- Mensah, G. B. (2023). Liability, Accountability, and Errors in AI Telemedicine. *Researchgate*. <https://doi.org/10.13140/RG.2.2.14088.23046>
- Meyers, B. A., & Vlachos, P. P. (2025). Flow measurements in clinical cardiac imaging. *Physical Review Fluids*, 10(2). <https://doi.org/10.1103/physrevfluids.10.020501>
- Muhammad Ali Muzammil, Javid, S., Azra Khan Afridi, Rupini Siddineni, Shahabi, M., Muhammad Haseeb, F.N.U. Fariha, Kumar, S., Zaveri, S., & Nashwan, A. J. (2024). Artificial intelligence-enhanced electrocardiography for accurate diagnosis and management of cardiovascular diseases. *Journal of Electrocardiology*, 83. <https://doi.org/10.1016/j.jelectrocard.2024.01.006>

- NHS. (2019). Cardiovascular disease. NHS Long Term Plan. <https://www.longterm-plan.nhs.uk/online-version/chapter-3-further-progress-on-care-quality-and-outcomes/better-care-for-major-health-conditions/cardiovascular-disease/>
- NHS. (2022, April 22). Cardiovascular disease. NHS; NHS. <https://www.nhs.uk/conditions/cardiovascular-disease/>
- Nori, L. P., Maddala Lohitha, Rama Rao Vadapalli, Brahmaiah Bonthagarala, Sudarshan Rao Nagineni, & Kalidindi, V. R. (2025). Revolutionizing Healthcare: The Impact of AI on Precision Medicine. *International Journal of Pharmaceutical Investigation*, 15(2), 334–343. <https://doi.org/10.5530/ijpi.20250100>
- Olawade, D. B., David-Olawade, A. C., Wada, O. Z., Asaolu, A. J., Adereni, T., & Ling, J. (2024). Artificial intelligence in healthcare delivery: Prospects and pitfalls. *Journal of Medicine, Surgery, and Public Health*, 3, 100108. <https://doi.org/10.1016/j.glmedi.2024.100108>
- Rajeev, C., & Natarajan, K. (2024). Predictive Models for Noncommunicable Diseases: Exploring the Roles of Machine Learning, Deep Learning, Generative AI, and Optimization. In P. Bhattacharya, H. Liu, P. K. Dutta, Joel, & G. Sethi (Eds.), *Revolutionizing Healthcare 5.0: The Power of Generative AI: Advancements in Patient Care Through Generative AI Algorithms* (pp. 357–377). Springer Nature Switzerland. https://doi.org/10.1007/9783031757716_23
- Rajpurkar, P., Irvin, J., Ball, R. L., Zhu, K., Yang, B., Mehta, H., Duan, T., Ding, D., Bagul, A., Langlotz, C. P., Patel, B. N., Yeom, K. W., Shpanskaya, K., Blankenberg, F. G., Seekins, J., Amrhein, T. J., Mong, D. A., Halabi, S. S., Zucker, E. J., & Ng, A. Y. (2018). Deep learning for chest radiograph diagnosis: A retrospective comparison of the CheXNeXt algorithm to practicing radiologists. *PLOS Medicine*, 15(11), e1002686. <https://doi.org/10.1371/journal.pmed.1002686>
- Ramón Luengo-Fernández, Marjan Walli-Attaei, Gray, A., Aleksandra Torbica, Maggioni, A. P., Radu Huculeci, Firoozeh Bairami, Aboyans, V., Timmis, A., Panos Vardas, & Leal, J. (2023). Economic burden of cardiovascular diseases in the European Union: a population-based cost study. *European Heart Journal*, 44(45). <https://doi.org/10.1093/eurheartj/ehad583>
- Rippe, J. M. (2018). Lifestyle Strategies for Risk Factor Reduction, Prevention, and Treatment of Cardiovascular Disease. *American Journal of Lifestyle Medicine*, 13(2), 204–212. <https://doi.org/10.1177/1559827618812395>

- Santos, J. D., Nobre, J. P., Ferreira, J. P., Inês, M., Henriques, M., Nuno Cardim, Villanueva, T., & Gonçalves, A. (2025). PRIMARY-HF: Heart Failure Screening in Primary Care using Point-of-Care. *Acta Médica Portuguesa*. <https://doi.org/10.20344/amp.22463>
- Sattar, Y., & Chhabra, L. (2023, June 5). Electrocardiogram. National Library of Medicine; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK549803/>
- Scoble, R. (2025). AI and the Digital Divide. *Unaligned Newsletter*. <https://www.unaligned.io/p/ai-and-the-digital-divide>
- Shabeer, H., Ali Haider, H. M., Khatri, T., Khan, N., Rafique, A. A., & Anjam, F. (2025). The Role of Artificial Intelligence in Early Diagnosis and Management of Cardiovascular Diseases. *Indus Journal of Bioscience Research*, 3(2), 213–224. <https://doi.org/10.70749/ijbr.v3i2.667>
- Shajari, S., Kuruvinashetti, K., Komeili, A., & Sundararaj, U. (2023). The emergence of AI-based wearable sensors for digital health technology: A review. *Sensors*, 23(23), 9498–9498. <https://doi.org/10.3390/s23239498>
- Talukder, M. A., Talaat, A. S., & Kazi, M. (2025). HXAI-ML: A Hybrid Explainable Artificial Intelligence Based Machine Learning Model For Cardiovascular Heart Disease Detection. *Results in Engineering*, 104370–104370. <https://doi.org/10.1016/j.rineng.2025.104370>
- Thakur, G. K., Khan, N., Anush, H., & Thakur, A. (2024). AI-Driven Predictive Models for Early Disease Detection and Prevention. *Proceedings of the 2024 International Conference on Knowledge Engineering and Applications.*, 27, 1–6. <https://doi.org/10.1109/ickecs61492.2024.10616851>
- The Agha Khan University Hospital. (2019). Cardiovascular Health in Pakistan: A Growing Concern. *Aku.edu*. <https://hospitals.aku.edu/pakistan/AboutUs/News/Pages/cardiovascular-health.aspx>
- Tian, Y., & Liu, H. (2025). Advances and challenges in echocardiographic diagnosis and management of cardiac amyloidosis. *The International Journal of Cardiovascular Imaging*. <https://doi.org/10.1007/s10554-025-03362-5>
- Tilala, M. H., Chenchala, P. K., Choppadandi, A., Kaur, J., Naguri, S., Saoji, R., & Devaguptapu, B. (2024). Ethical Considerations in the Use of Artificial Intelligence and Machine Learning in Health Care: A Comprehensive Review. *Cureus*, 16(6), e62443. <https://doi.org/10.7759/cureus.62443>

- Topol, E. J. (2019). *Deep Medicine : How Artificial Intelligence Can Make Healthcare Human Again*. Basic Books.
- Ueda, D., Kakinuma, T., Fujita, S., Kamagata, K., Fushimi, Y., Ito, R., Matsui, Y., Nozaki, T., Nakaura, T., Fujima, N., Tatsugami, F., Yanagawa, M., Hirata, K., Yamada, A., Tsuboyama, T., Kawamura, M., Fujioka, T., & Naganawa, S. (2023). Fairness of Artificial Intelligence in healthcare: Review and Recommendations. *Japanese Journal of Radiology*, 42(1). <https://doi.org/10.1007/s11604-023-01474-3>
- Vaghefi, E., Squirrell, D., An, S., Yang, S., & Marshall, J. (2022). Replacing the Framingham-based equation for prediction of cardiovascular disease risk and adverse outcome by using artificial intelligence and retinal imaging. *ArXiv.org*. https://arxiv.org/abs/2207.14685?utm_source=chatgpt.com
- Vo, D.-K., & Trinh, L. (2024). Advances in Wearable Biosensors for Healthcare: Current Trends, Applications, and Future Perspectives. *Biosensors*, 14(11), 560–560. <https://doi.org/10.3390/bios14110560>
- WHO. (2023). Regulatory considerations on artificial intelligence for health. <https://iris.who.int/bitstream/handle/10665/373421/9789240078871-eng.pdf>
- Williamson, S. M., & Prybutok, V. (2024). Balancing Privacy and Progress: A Review of Privacy Challenges, Systemic Oversight, and Patient Perceptions in AI-Driven Healthcare. *Applied Sciences*, 14(2), 675. <https://www.mdpi.com/2076-3417/14/2/675>
- World Health Organization. (2021, June 11). Cardiovascular Diseases (CVDs). World Health Organization. [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))
- World Heart Federation. (n.d.). WORLD HEART VISION 2030 DRIVING POLICY CHANGE 2. <https://world-heart-federation.org/wp-content/uploads/World-Heart-Vision-2030.pdf>
- Wurie, H. R., & Cappuccio, F. P. (2012). Cardiovascular disease in low- and middle-income countries: an urgent priority. *Ethnicity & Health*, 17(6), 543–550. <https://doi.org/10.1080/13557858.2012.778642>
- Xia, B., Innab, N., Kandasamy, V., Ahmadian, A., & Ferrara, M. (2024). Intelligent cardiovascular disease diagnosis using deep learning enhanced neural network with ant colony optimization. *Scientific Reports*, 14(1). <https://doi.org/10.1038/s41598-024-71932-z>

Appendices

Appendix 1. Interview Questions

1. What do you see as the biggest challenges in adopting AI-driven preventive healthcare solutions for cardiovascular diagnostics in the current healthcare system?
2. How do you think AI-powered diagnostics, such as machine learning and deep learning models, can improve early detection and risk assessment in cardiovascular diseases?
3. From a business perspective, what are the key factors that could drive or hinder the scalability and affordability of AI-driven cardiovascular diagnostic solutions?
4. What role do regulatory and ethical concerns, such as data privacy and AI transparency, play in the adoption of AI in preventive healthcare?
5. In your opinion, what are the most promising business opportunities that AI can offer in preventive cardiovascular healthcare?

.